CCX 140

Drug Profile

CCX 140

Alternative Names: CCX-140B; CCX140

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Vifor
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Research Kidney disorders
  • No development reported Type 2 diabetes mellitus
  • Discontinued Multiple sclerosis; Vascular restenosis

Most Recent Events

  • 09 Jan 2017 ChemoCentryx plans clinical trials in Focal segmental glomerulosclerosis
  • 23 Dec 2016 Early research in Kidney disorders (rare) in USA (PO)
  • 23 Dec 2016 Vifor Pharma and ChemoCentryx agree to co-promote CCX 140 for Kidney disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top